Abbott Laboratories stock trades at EUR 88.71 versus EUR 88.77, minus 0.07 percent

Published on 09/29/2026 at 15:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott Laboratories stock was at EUR 88.71, versus the EUR 88.77 prior close and minus 0.07 percent on September 29, 2026. Q2 revenue rose 13.0 percent to USD 12.593 billion, while adjusted EPS reached USD 1.31.

Modernes Diagnostik-Labor Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 zeigt modernes Diagnostik-Labor mit Wissenschaftlern in weißen Laborkitteln an Analysesystemen, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) was trading at EUR 88.71 at Lang & Schwarz on September 29, 2026 at 3:12 p.m. CEST, minus 0.07 percent versus the prior close of EUR 88.77. The company enters the next earnings checkpoint with higher full-year adjusted EPS guidance and a Medical Devices segment that is carrying more of the growth story.

Q2 revenue reaches USD 12.593 billion

According to StockTitan on July 16, 2026, Abbott reported second-quarter net sales of USD 12.593 billion, up 13.0 percent from the prior-year quarter. GAAP diluted EPS was USD 0.53, while adjusted diluted EPS reached USD 1.31.

Fortune reported that Abbott raised full-year 2026 adjusted EPS guidance to USD 5.45-5.60 and reaffirmed comparable sales growth guidance of 6.5-7.5 percent in the July 16, 2026 earnings call. Third-quarter adjusted EPS guidance was set at USD 1.38-1.46.

Medical Devices grows 8.4 percent

The operating mix is becoming more important than the headline revenue increase. The Motley Fool said on September 18, 2026 that Medical Devices comparable sales grew 8.4 percent in Q2, with electrophysiology helping the segment approach USD 6 billion in quarterly sales. Nutrition and Rapid and Molecular Diagnostics declined, leaving faster-growing device and cancer-screening operations to support the expansion.

The same The Motley Fool report cited TD Cowen raising its target to USD 135.00 from USD 115.00, Citi lifting its target to USD 125.00 from USD 112.00, and Wolfe Research upgrading Abbott to Outperform with a USD 130.00 target. Those targets show that the earnings debate centers on sustaining the second-half acceleration rather than on the Q2 revenue comparison alone.

Next earnings date is October 21

Investing.com lists October 21, 2026 as Abbott's next earnings date. The current market snapshot places the stock's 52-week range at USD 81.97-135.45 and market capitalization at USD 174.7 billion as of September 29, 2026.

Abbott Laboratories stock was trading at EUR 88.71 at Lang & Schwarz on September 29, 2026 at 3:12 p.m. CEST, minus 0.07 percent versus the prior close of EUR 88.77.